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Fatty acids are an important class of signaling molecules regulating key aspects of whole body
metabolism and physiology. In this issue, Yore et al. report a group of branched fatty acid esters
of hydroxy fatty acids that regulate insulin secretion and glucose uptake through the activation
of GPR120.Cooking up drugs with the potential to
prevent or treat obesity and type 2 dia-
betes has proven a challenge that might
have even been too great for Walter
White, the resourceful chemist of the
TV’s Breaking Bad. New discoveries
focusing on fat cells, however, may offer
hope. White adipose tissue, by virtue of
its ability to store energy, is central to
the regulation of lipid and glucose homeo-
stasis during the fed and fasted state.
Recently, fat has also received attention
for its ability to increase energy expendi-
ture and counteract the development of
obesity and type 2 diabetes. This has
been driven mainly by the identification
of functional human brown adipose tis-
sue. Nevertheless, dysfunctional white
adipose tissue remains one of the primary
causes of insulin resistance associated
with obesity and the metabolic syndrome.
Pharmacological interventions to treat or
reverse the consequences of obesity
and type 2 diabetes might be more likely
to succeed if their target includes white
adipose tissue function. In the current
issue of Cell, Yore et al. (2014) offer such
a functional target with the identification
of a new class of branched fatty acid
esters of hydroxy fatty acids (FAHFA).
FAHFA are synthesized in response to
Glut4-mediated glucose uptake and acti-
vation of the transcription factor ChREBP
(Carbohydrate-responsive element-bind-
ing protein) in white adipocytes and
released in the blood to enhance insulin
secretion and increase insulin-stimulated
glucose uptake into adipose tissue
through the activation of Gpr120 (Figure 1)
(Yore et al., 2014). Hence, the authors
extend the repertoire of white adipocyte
endocrine factors, as well as those from238 Cell 159, October 9, 2014 ª2014 Elsevieother tissues, to include a previously
unrecognized class of fatty acid esters
that function as important regulators of
glucose homeostasis.
Regulation of glucose and lipid homeo-
stasis is a key function of adipocytes, one
that critically depends on insulin-medi-
ated glucose uptake by Glut4. In line
with this, downregulation of Glut4 in adi-
pose tissue is one of the earliest events
in the pathogenesis of insulin resistance
and type 2 diabetes. The key role of this
pathway is underscored by the ability of
adipose tissue selective overexpression
of Glut4 (AG4OX mice) to rescue glucose
intolerance and insulin resistance in
muscle-specific Glut4 knockout mice
(Carvalho et al., 2005). However, contrary
to the general association of increased
free fatty acids with insulin resistance,
these mice show improved insulin sensi-
tivity and increased serum-free fatty
acids. Subsequently, Herman et al.
(2012) established that ChREBPmediates
the beneficial effects of enhanced Glut4-
mediated glucose uptake in adipocytes
by activating de novo lipogenesis. This
suggests that in addition to the release
of metabolically unfavorable fatty acid
metabolites like long chain fatty acid
acyl-CoA, diacylglycerol and ceramides,
adipocytes could secrete lipid species
that are metabolically beneficial, a notion
supported by data from the laboratory of
Gokhan Hotamisligil, who identified pal-
mitoleate as an adipose-derived lipid hor-
mone improving insulin action in muscle
and liver (Cao et al., 2008). Thus, in addi-
tion to the various hormones and cyto-
kines released from adipocytes, lipids,
as lipokines, could act as important regu-
lators of whole body metabolism.r Inc.To test their hypothesis, Yore et al. set
out to measure adipose lipids in AG4OX
mice using an advanced, untargeted
mass spectrometry lipidomics approach,
from which they discover a previously un-
identified class of fatty acid-hydroxy fatty
acids (FAHFAs), consisting of 16 different
members. Among this group, palmitic
acid-hydroxy stearic acids (PAHSA) are
the most highly upregulated fatty acids
in adipose tissue of AG4OX mice, which
led the authors to investigate the biolog-
ical regulation and activity of PAHSAs.
There are a total of eight different
PAHSA isomers in mouse tissues, and
each isomer is defined by the position of
the ester at a different carbon of the hy-
droxystearic acid (HSA) in the PAHSA
structure. PAHSA levels are reduced
with diet-induced obesity and insulin
resistance in both mice and humans.
These data alone are significant, because
they establish PAHSAs as new bio-
markers for insulin resistance. Moreover,
the correlation between high PAHSA
levels and insulin sensitivity prompted
theauthors tomeasure the effects of these
lipids in vivo. Oral delivery of 9-PAHSA
and 5-PAHSA to mice enhances glucose
tolerance through their ability to bind
to and activate the Gpr120 long-chain
fatty acid receptor. In line with this
potential function as a natural Gpr120
ligand, PAHSAs enhance insulin secretion
through their action on pancreatic islets
and Glp-1-secreting intestinal enteroen-
docrine cells. In addition, similar to the
effects ofu-3 fatty acids, PAHSAs reduce
lipopolysaccharide- and high-fat-diet-
induced inflammation. Further evidence
for a connection between PAHSAs and
GPR120 is established by demonstrating
Figure 1. PAHSAs Regulate Multiple Com-
ponents of Glucose Homeostasis
In response to Glut4-mediated glucose uptake and
ChREBP dependent mechanisms palmitic acid-
hydroxy stearic acid (PASHA) isomers are pro-
duced and secreted from adipose tissue in
response to Glut4-mediated glucose uptake and
activation of ChREBP. PASHAs can activate
Gpr120 on adipocytes and enhance insulin-medi-
ated glucose uptake via Glut4. Serum PASHAs
also show endocrine effects that enhance insulin
secretion via activation of Gpr120 from pancreatic
islets or via intestinal L-cells that induces Glp-1
secretion. The exact cellular types (b- or d-cells) in
pancreatic islets targeted by PASHAs remain to be
determined. Thus, increased release of PAHSAs
regulates glucose homeostasis directly on adipo-
cytes through increased insulin secretion and
could thereby also indirectly impact on insulin
action in skeletal muscle and liver.that insulin-stimulated Glut4 translocation
andglucoseuptake in adipocytes requires
PAHSA-induced GPR120 signaling.
Overall, they not only describe the
origin and regulation of an entirely new
class of signaling metabolites during
different metabolic states, like fasting
and high fat diet feeding, but also identify
Gpr120 as a FAHFA receptor.
Yore et al. establish PAHSAs as Gpr120
ligands, defining their physiological func-
tions in increasing insulin secretion and
insulin-stimulated glucose transport,
thereby modulating glucose homeosta-
sis. However, some of the observed re-
sults might not be fully explained by signal
mediation through Gpr120. The regulation
of Glp-1 secretion, for example, has beenassociated with both activation of Gpr120
and the functionally closely related Gpr40
(Milligan et al., 2014). Moreover, recently
Oh da et al. (2014) described a Gpr120-
selective agonist that confers an improve-
ment of glucose tolerance similar to
PAHSAs and fails to directly induce
Glp-1 secretion. Thus, using Gpr120-defi-
cient animal models it will be interesting to
determine if PAHSAs are endogenous
Gpr40 ligands too. PAHSAs could also
enable the development of powerful coa-
gonists that would simultaneously acti-
vate both receptors and, similar to what
we have shown for GIP/Glp-1 dual incretin
agonists (Finan et al., 2013), utilize the
positive consequences of these receptor
activities while reducing the risks of ligand
resistance and toxicity. This seems espe-
cially important for the activation of
Gpr40, as evidenced by the recent failure
of a clinical phase III study using Fasigli-
fam (TAK-875) due to concerns about liver
toxicity (Milligan et al., 2014).
In addition to their role in Glp-1 secre-
tion, PAHSAs are also directly associated
with insulin secretion from pancreatic
b-cells. However, recent data suggest
that activation of Gpr120 to regulate insu-
lin secretion may be mediated mainly
through inhibition of somatostatin release
from d-cells rather than direct action
on b-cells, further indicating a potential
agonistic action of PAHSAs on Gpr40
(Stone et al., 2014), or other fatty acid
receptors.
Aside from their pharmacological
action, the exact pathways and enzymes
responsible for the production and
release of FAHFAs remain unknown but
are an important piece of the puzzle. The
current study demonstrates that enzymes
within adipose and liver lysates produce
similar amounts of PAHSAs from exoge-
nous substrates, yet tissue levels are
dramatically different, indicating that
the substrate might be the rate-limiting
factor determining tissue abundance.
The synthesis of FAHFAs in nonadipose
tissues, suggests that FAHFAs, like other
signaling lipids, (Gillum et al., 2008; Rodrı´-
guez de Fonseca et al., 2001), are not spe-
cific to adipocytes but can be produced
and released from a variety of tissues.
Thus, FAHFAs from nonadipose tissues
could also contribute to the endocrine ef-
fects of these lipids. Yore et al. show that
PAHSA levels change dramatically withinCell 15adipose tissue upon fasting and high-fat-
diet feeding. Conversely, overall serum
PAHSA levels remain unchanged upon
these interventions, indicating that indi-
vidual PAHSA isomers might show selec-
tive, nonredundant functions to mediate
changes in Glp-1 and insulin secretion.
To date, proteins and peptides remain
the focus of endocrinologists who seek
to decipher the communication pathways
between organs and develop new thera-
peutic strategies. However, new structur-
ally diverse sets of metabolites, either
from within the body or from gut micro-
biota, have emerged as important regula-
tors of metabolism. The identification of
branched fatty-acid-esters of hydroxy-
fatty-acids as endocrine factors highlights
the significance of metabolomics studies
in revealing new targets for the treatment
of type 2 diabetes and the metabolic syn-
drome beyond genomics and proteomics.
Identifying other important, and likely ex-
isting, bioactive metabolites and using
that knowledge to develop personalized
therapy options to treat obesity andmeta-
bolic syndrome are an opportunity we
can’t afford to miss. For now, white adi-
pose tissue has taught us another impor-
tant (bio-)chemical lesson we suspect
evenWalter White would have found quite
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Nuclear pore assembly can go awry, but how the cell handles defective intermediates has been
an ongoing question. In this issue, Lusk and colleagues describe a surveillance pathway during
nuclear pore assembly and, in doing so, identify a new role for proteins that function at the endo-
some and plasma membrane.Cells eliminate defective products through
quality control mechanisms to ensure that
biochemical pathways operate smoothly.
One well-studied example of quality con-
trol is endoplasmic reticulum-associated
degradation (ERAD), an intricate process
by which secretory and membrane pro-
teins that fail to fold properly within the
confines of the endoplasmic reticulum
are extruded into the cytosol for disposal
by proteasomes (Ruggiano et al., 2014).
ERAD is but one way in which cells guard
against abnormal accumulations of pro-
teins that might be nonfunctional or could
potentially be dangerous. More pathways
for quality control, however, remain to be
discovered. In this issue of Cell, Webster
et al. describe a new quality control path-
way to eliminate nascent nuclear pore
complexes (NPCs) that have failed to
assemble properly and, in doing so, they
unexpectedly broaden the realm of activ-
ities for a protein machinery that was
originally discovered to function at endo-
somes.
Hundreds of NPCs perforate the dou-
ble-membrane barrier created by the nu-
clear envelope to form aqueous channels
that connect the cytoplasm with the inte-
rior of the nucleus. Given their sheer abun-dance, NPCs are constantly undergoing
assembly in proliferating cells (Fernan-
dez-Martinez and Rout, 2009). Humans
and other eukaryotes undergo open
mitosis during which NPCs are disas-
sembled at the onset of mitosis into their
constituent proteins, the nucleoporins. At
the end of mitosis, these nucleoporins
reassemble into new NPCs in the newly
formed nucleus established in each
daughter cell. Given that mitosis effec-
tively doubles the amount of nuclearmem-
brane, NPCsmust also be assembled with
newly synthesized nucleoporins since as-
sembly with recycled nucleoporins is not
sufficient to maintain the density of NPCs
needed in the nuclei of daughter cells.
NPC assembly is even more reliant on
newly synthesized nucleoporins in the
budding yeast Saccharomyces cerevisiae,
which has a closed mitosis where the
nuclear membrane remains intact, and
pre-existing NPCs do not undergo disas-
sembly.
In humans and yeast, defects in NPC
assembly can result in aggregates of nu-
cleoporins that decrease nuclear integrity,
which is linked to a reduction in cellular
replicative lifespan (Fernandez-Martinez
and Rout, 2009). In this issue of Cell, thestudy by Webster et al. (2014) shows that
in yeast, misassembled NPCs accumulate
in a storage compartment they term the
SINC, for storage of improperly assem-
bled nuclear pore complexes. SINCs are
preferentially retained in mother yeast
cells during mitosis. This apparent act of
altruism prevents defective NPCs from
being passed on to progeny but saddles
parental cells with the prospect of
decreasedNPCutility as they age. Indeed,
the accumulation of SINCs in mother
yeast cells correlates with a reduction in
nucleocytoplasmic transport.
Unexpectedly, defectiveNPC assembly
intermediates can avoid the SINC alto-
gether through a pathway that involves
the endosomal sorting complexes re-
quired for transport (ESCRTs). As their
name implies, ESCRTs were originally
identified because of their function at
endosomes. In the canonical ESCRT
pathway, five distinct protein complexes
cooperate in the creation of vesicles that
bud into the endosome lumen, and these
intralumenal vesicles are destroyed in
the interior of the lysosome upon endoly-
sosomal fusion (Figure 1). However,
ESCRTs have since been found to operate
at the plasma membrane, where they are
